Steatotic Liver Disease Clinical Trial
Official title:
German SLD-Registry Characterization of Patients With Steatotic Liver Disease (SLD) in Germany - Phase 1 (Observation of the Natural Course)
Characterization of patients with steatotic liver disease (SLD) The German SLD-Registry (Deutsches SLD-Register) a project of the German Liver Foundation (Deutsche Leberstiftung), managed by Leberstiftungs-GmbH Deutschland. The German NAFLD-Registry is financially supported by: Advanz Pharma Specialty Medicine Deutschland GmbH und Gilead Sciences GmbH (Grant to German Livber Foundation) sowie Novo Nordisk Pharma GmbH (directly via Leberstiftungs-GmbH).
The following data can be documented: - physical examination and vital parameters (e.g. age, weight) - comorbidities (e.g. diabetes mellitus, cardiovascular disease) - comedication (treatment of comorbidities related to SLD) - laboratory values (e.g. liver function tests, creatinine) - genetic variants (e.g. PNPLA3) - liver diagnostics (e.g. histological findings, sonographic findings) - lifestyle (alcohol consumption, physical activity) - health related quality of life (SF-36 questionnaire) ;